Paion AG (FRA:PA8K)

Market Cap	64.20K
Revenue (ttm)	14.81M
Net Income (ttm)	-19.86M
Shares Out	7.13M
EPS (ttm)	-2.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,400
Average Volume	796
Open	0.0090
Previous Close	0.0102
Day's Range	0.0090 - 0.0102
52-Week Range	0.0002 - 0.0498
Beta	1.73
RSI	48.80
Earnings Date	Aug 29, 2025

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distribu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PA8K

Financial Performance

In 2022, Paion AG's revenue was 33.25 million, an increase of 366.44% compared to the previous year's 7.13 million. Losses were -579,000, -97.34% less than in 2021.